News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Hidehito Horinouchi: Thank you so much Solange Peters for coming to Japan
Photo taken from: Hidehito Horinouchi/X
Feb 26, 2024, 09:51

Hidehito Horinouchi: Thank you so much Solange Peters for coming to Japan

Hidehito Horinouchi, Medical Oncologist, Assistant Chief in the Department of Thoracic Oncology at National Cancer Center Hospital, Japan, made the following post on X:

“Thank you so much Solange Peters for coming to Japan JSMO2024 while Santa Monica is in the middle of the excitement of TTLC24.”

Source: Hidehito Horinouchi/X

cancer Hidehito Horinouchi OncoDaily Oncology Solange Peters
Special Coverage
Blog
Nov 1, 2024, 20:27
Amy Oxentenko: Honored to be inducted as President of the American College of Gastroenterology
Blog
Nov 1, 2024, 20:22
Yan Leyfman: Honored to present our research at the 2024 Lymphoma, Leukemia and Myeloma Congress
Blog
Nov 1, 2024, 20:05
The Official Programme for Advancing Paediatric Oncology on Children’s Rights Day is Out - SIOP Europe
Blog
Nov 1, 2024, 19:20
Chandler Park: Dr. Petros Grivas answers the most important question for junior faculty
Blog
Nov 1, 2024, 19:12
ESTRO: Toxicity Profile of Immune Therapy Combined with Radiotherapy
Insight
Nov 1, 2024, 17:59
Ajay Major: Collect long-term follow-up data in survivors of Hodgkin lymphoma with the MyHodgkin MyHealth app
Blog
Nov 1, 2024, 17:52
Habib Nehmé: Strengthening Presence in Saudi Arabia’s Radiotherapy and Oncology Market
Blog
Nov 1, 2024, 17:46
Hidehito Horinouchi: Early Stage NSCLC at ACLC24 session
Blog
Nov 1, 2024, 17:41
Yelak Biru's interview with News 9 about the work IMF does
Insight
Nov 1, 2024, 17:31
Francisco Esteva: ADCs are making waves in the fight against advanced HER2+ breast cancer
Blog
Nov 1, 2024, 17:27
Alcohol consumption increases the risk of cancer at 7 sites - IARC
Blog
Nov 1, 2024, 17:17
Raul Cordoba: Valemetostat for relapsed or refractory peripheral T-cell lymphoma